Breakthrough Invasive Mould Infections Under Posaconazole Prophylaxis in Patients With Haematologic Malignancies: A Case-Control Study.

ABSTRACT:

Background

Posaconazole (POS) prophylaxis is recommended for the prevention of invasive mould infections among patients with haematologic cancer and prolonged neutropenia or following allogeneic haematopoietic cell transplantation. Albeit rare, breakthrough invasive mould infections (bIMI) are associated with high mortality rates.

Objectives

To assess the epidemiology, causes and outcomes of bIMI under POS prophylaxis.

Patients/methods

Haematologic cancer patients with a diagnosis of proven/probable bIMI while receiving POS prophylaxis for ≥ 7 days were retrospectively included in five hospitals (Switzerland and Germany). For each bIMI case, one to two non-bIMI controls receiving POS prophylaxis for the same haematologic condition were included.

Results

A total

SUBMITTER: Marchetti C 

PROVIDER: S-EPMC12523195 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature